Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson's Disease

[Bolt_Upright]

Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson's Disease: A Network Pharmacological Approach Sept 2021 ncbi.nlm.nih.gov/pmc/articl...

Conclusion

In summary, we applied network pharmacology to identify 87 related targets of Idebenone against PD. Further analysis revealed that MAPK1 and AKT1 could bind tightly with Idebenone. In addition, in vitro experiments showed that Idebenone may reduce the level of α-synuclein through the activation of autophagy. The underlying mechanism may relate to the suppression of the AKT/mTOR pathway. Our work provides new insights on the therapeutic mechanism of Idebenone treatment against PD.

Note from Bolt: I have some Idebenone. I know they have some trials going on trying it to prevent progression of RBD to PD. I stopped taking it as I wanted to limit my stack size. Reconsidering.

[Nitro53]

Pardon my ignorance but English please.🙂

[Bolt_Upright in reply to Nitro53]

"Idebenone may reduce the level of α-synuclein".

It might be something.

I might add it to my "occasional supplements" list.

I have not been diagnosed with PD. I have REM Sleep Behavior Disorder, which my doctor says is Pre-PD.